-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempus AI: 3 Key Takeaways for Long-Term Investors

The Motley Fool·11/19/2026 06:55:01
Listen to the news

Key Points

  • Tempus signed data agreements expected to generate $193 million over 5 years.

  • Approved pricing moves will add $80 million in oncology ASP during 2027.

  • Third-quarter revenue grew 23% year over year to $411.5 million.

On its third-quarter 2026 earnings call, held on Nov. 2, 2026, Tempus AI (NASDAQ:TEM) reported total revenue of $411.5 million, up 23% year over year. The diagnostic and data platform generated $25.6 million in adjusted EBITDA, or earnings before interest, taxes, depreciation, and amortization.

Rising test prices and multiyear biopharma licensing agreements provide predictable funding for future software development. Three things management said on the call stand out.

1. Multiyear Biopharma Deals Expand High-Margin Data Licensing

Data and applications revenue rose 33% year over year to $108 million, driven by long-term licensing of real-world patient records to biopharma partners, such as Pathos AI. Multiyear collaborations with major pharmaceutical companies secure predictable cash flows as clients train artificial intelligence models inside the company's platform.

Through this collaboration, Pathos is paying Tempus $55 million over a 5-year term. As a result, over the next approximately 5 years, we expect to generate $193 million of additional data and applications revenue from these agreements alone.
-- Eric Lefkofsky, Founder and Chief Executive Officer

2. Regulatory Approvals Drive Oncology Average Selling Price Tailwinds

Reimbursement expansion for clinical tests directly boosts diagnostic gross margins without requiring higher sales expenses. Tempus expects substantial gains in average selling prices (ASPs) as its XT solid tumor profiling test transitions to approved regulatory pricing from the Food and Drug Administration (FDA).

Given the expansion of our FDA approval to include tumor-only for XT test, that updated pricing will kick in on January 1 and allow us to move the remaining XT over. That gives us about $80 million of uplift in oncology ASP in 2027.
-- Jim Rogers, Chief Financial Officer

3. Operational Scale Delivers Positive Adjusted EBITDA Pivots

Gross profit growth outpaced operational investments during the quarter, helping the business reach positive operating profit targets. Generating positive adjusted EBITDA shows that expanding diagnostic test volumes drop directly down to the bottom line.

We had long suspected that with gross profit dollar growth outpacing our investments, we would eventually turn the corner and be able to generate meaningful EBITDA. This quarter, we made the turn.
-- Eric Lefkofsky, Founder and Chief Executive Officer

Looking Ahead

Compounding technology investments and clinical datasets reinforce competitive positioning across oncology markets. Strategic execution prioritizes gross profit reinvestment to maintain diagnostic leadership.

The scale of our business and the breadth of our portfolio has allowed us to build a significant data moat. By compounding a decade of investment in our AI capabilities, we deliver solutions that grow more powerful with every patient touch point, cementing our position as an indispensable engine for healthcare innovation.
-- Eric Lefkofsky, Founder and Chief Executive Officer

Sustained revenue expansion hinges on long-term execution across clinical sequencing and data licensing.

At the end of the day, if you can sustain kind of 25% growth over a decade over another decade, you will build a really large business. And we think we are building a really large business.
-- Eric Lefkofsky, Founder and Chief Executive Officer

The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.